morphine sulfate

FDA Drug Profile — Morphine Sulfate, Morphine sulfate, MS Contin, Duramorph, INFUMORPH 500

morphine sulfate is listed in the FDA National Drug Code directory with 40 NDC codes, marketed under brand names including Morphine Sulfate, Morphine sulfate, MS Contin. Available dosage forms: capsule, extended release, tablet, film coated, extended release, solution, injection, tablet.

Drug details

Generic Name
morphine sulfate
Brand Names
Morphine Sulfate, Morphine sulfate, MS Contin, Duramorph, INFUMORPH 500, INFUMORPH 200
Application Number
ANDA203158
Sponsor
Nortec Development Associates, Inc.
NDC Codes
40
Dosage Forms
CAPSULE, EXTENDED RELEASE, TABLET, FILM COATED, EXTENDED RELEASE, SOLUTION, INJECTION, TABLET, INJECTION, SOLUTION
Routes
ORAL, EPIDURAL, INTRATHECAL, INTRAVENOUS
Active Ingredients
MORPHINE SULFATE

Indications and Usage

1 INDICATIONS AND USAGE Morphine Sulfate Injection is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Limitations of Use : • Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including Morphine Sulfate Injection, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) Morphine Sulfate Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use • Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration [see Warnings and Precautions ( 5.1 )], and persist over the course of therapy, reserve opioid analgesics, including Morphine Sulfate Injection, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.